Abstract: Engineered tissue constructs are inherently limited by their lack of microvascularization. Evidence suggests that combining a scaffold material with cells and their cell-secreted signals instigates tubule formation, and various strategies can be employed to tailor the vascular response. This review focuses on rationally designed materials capable of supporting functional neovessel formation and stabilization. Biomaterial scaffolds and their use as growth factor delivery systems are discussed, as well as other functional enhancement strategies to direct cellular responses for effective formation of a mature vascular network.
THE NEED FOR THERAPEUTIC ANGIOGENESIS
Although organ transplantation saves thousands of lives each year, over 110,000 patients are currently on the transplant list, and a new name is added every thirteen minutes. Strikingly, eighteen people die each day awaiting an organ [1] . The increasing demand for donated organs cannot be met by current supplies from cadaveric and living donors. Concerted efforts in the field of tissue engineering aim to fill this void by replacing injured tissues and organs with functional engineered counterparts. Although several engineered tissues have been fabricated to date [3] [4] [5] [6] [7] , successes are limited to thin and/or avascular tissues, such as skin and cartilage. In these examples, oxygen, nutrients, and wastes can diffuse without a functional microvascular system. Diffusion is only capable of transporting these elements a distance of a few hundred microns however, meaning that as the engineered tissue mass increases, cells in the regions farthest from nutrient source will suffer. Successful development of thick or more complex tissues, such as lung, liver, or heart, will require a better understanding of how to encourage vascularization in engineered matrices. Therapeutic angiogenesis attempts to induce new blood vessel formation using three basic components: (1) growth factors, (2) scaffolds, and (3) cells [9] , and a growing body of tissue engineering research demonstrates the formation of functional and stable tubule networks that can be used for fabrication of more complex engineered tissues.
BIOLOGY OF THE MICROVASCULATURE
When designing a strategy to induce microvasculature formation in engineered tissues, it is important to understand the basic biological factors contributing to vessel function in vivo. Capillaries, the smallest of the vasculature components, are responsible for providing nourishment to the remote regions of tissues not penetrated by larger vessels. Capillaries are composed of endothelial cells, pericytes, and a thin *Address correspondence to this author at the Department of Bioengineering, Rice University, 6100 Main Street, Houston, TX 77005, USA; Tel: 713-348-5955; Fax: 713-348-5877; E-mail: jwest@rice.edu basement membrane. A monolayer of thrombo-resistant endothelial cells forms a selectively permeable barrier and functions to control leukocyte and platelet interactions, blood flow, and vessel tone [10] . The exterior walls of capillaries are lined with a single layer of pericytes, a type of mural cell analogous to the smooth muscle cells found in larger vessels [11] . Primarily, pericytes are responsible for the production of basement membrane proteins, but similar to their mural cell counterparts, pericytes also have a contractile function to help regulate blood flow and vessel permeability. Each pericyte is positioned to cover several endothelial cells in an "umbrella-like" manner as shown in Fig. (1C) . With less than 20 nm between pericytes and endothelial cells, these support cells are able to regulate permeability but also enhance general microvascular integrity [11] . Vessels lacking pericytes exhibit leaky and impaired perfusion due to abnormal endothelial junctions and can present with endothelial hyperplasia and hypervariable diameter [12] , further emphasizing the critical role of the support cell in vessel function.
Blood vessels form in vivo during the various stages of development, but also in the mature organism as part of the healing response or as necessary in the normal maintenance of homeostasis. New capillaries arise from either of two basic processes as depicted in Fig. (1) . Vasculogenesis is de novo formation of vessels from bone marrow-derived endothelial progenitor cells. Alternatively, in angiogenesis, sprouts extend from pre-existing capillaries to form new vessels. In the final stages of both pathways, pericytes derived from either endothelial progenitor cells or pre-existing capillaries are recruited to stabilize the neovessels. A combination of cells and factors work in concert to bring about these changes in tissues, and it is these mechanisms that are exploited in strategies to engineer the microvasculature in novel biomaterials.
THE ROLE OF GROWTH FACTORS IN VESSEL DEVELOPMENT
Soluble factors have essential roles in the development of new vessels. Consider for example the process of angiogenesis, which is portrayed in Fig. (2) . The impetus for extension of vascular sprouts is a gradient of cell-secreted signals that originates in the area of ischemic tissue (A). The signal directs a disruption of the connection between endothelial cells and pericytes, with the tip endothelial cell initiating the detachment from the basement membrane (B). Next the endothelial cells migrate and extend filapodia in response to the released proteins, and vacuoles form and fuse to create tubule lumen (C). Finally pericytes are recruited to lay basement membrane proteins (D) [13] . The resulting vessels are stabilized and remodeled as necessary, and afterwards endothelial cells return to their normal quiescent state. Many growth factors have been identified as contributing to the processes of vasculogenesis and angiogenesis. Three commonly studied signaling molecules for applications in tissue engineering are vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF). VEGF, considered the key angiogenic factor, stimulates endothelial cells to migrate, proliferate, and differentiate [14] . VEGF-A, the most characterized VEGF molecule, exists in five isoforms: VEGF 121 is completely soluble, VEGF 165 is mostly soluble but also has affinity for heparin sulfate proteoglycans on cell surfaces, whereas VEGF 145, VEGF 189 , and VEGF 206 all remain sequestered on the cell surface due to their high affinities for heparin [15] . Knockout mice confirm the importance of VEGF by demonstrating that a mouse lacking even one VEGF gene fails to develop past the early embryonic stages [16] . A suboptimal tissue oxygen level is the most important inducer of VEGF expression in vivo, mediated by the hypoxiainducible factors HIF-1 and HIF-2 along with an increase in mRNA stability [17] . VEGF has been widely used to induce angiogenesis, but unfortunately vessels developing in response to this factor alone are most often unstable, leaky, and hemorrhagic [3] , indicating that a more complex signaling strategy is warranted. Like VEGF, fibroblast growth factor (FGF) is also known for its ability to initiate microvasculature formation. Notably, FGF was the first angiogenic growth factor to be discovered and represents a family consisting of over 20 molecules, of which FGF-2, or basic FGF, is the primary member involved in angiogenesis. FGF-2 stimulates endothelial cell proliferation and migration and regulates expression of other key angiogenic molecules, such as collagenases, 1 integrins, and urokinase type plasminogen activator [18] . The growth factor also induces migration and proliferation of smooth muscle cells [19] . Like VEGF, hypoxic conditions are a trigger for the release of FGF-2. As FGF-2 is released from macrophages, endothelial cells are stimulated to proliferate and drive capillary formation.
Contrary to growth factors like FGF and VEGF, which are primarily known to initiate angiogenesis, platelet-derived growth factor (PDGF) is involved in the later stages of vessel establishment characterized by stabilization and remodeling. Identified as a key protein secreted from platelets in the 1970s, PDGF forms homo-and heterodimers of A-and Bpolypeptide chains. Two PDGF receptors exist, and their ligand-induced dimerization initiates receptor autophosphorylation, which in turn induces widespread effects throughout the body, especially in the development of the kidneys, lungs, CNS, and blood vessels. Specific to the vascular system, endothelial cells not only produce PDGF but also display PDGF receptors [20] . The well-studied homodimer PDGF-BB is involved in neovessel stabilization and recruitment of pericytes and contributes to functionalization by promoting anastomoses. PDGF also induces pericyte production of extracellular matrix (ECM) molecules (e.g. fibronectin, collagen, and proteoglycans) that constitute the basement membrane of capillaries. Furthermore, PDGF stimulates fibroblasts to produce and secrete collagenases which function in the remodeling of vessels and surrounding tissue during the final stages of microvasculature establishment. Highlighting its importance, studies of mice lacking the PDGF-B chain are characterized by defective blood vessels that exhibit microaneurysms, likely as a result of the inability of the neovessels to attract stabilizing pericytes [21] and proceed successfully through the final stages of development. Recent work studying these later stages of formation has concentrated on another version of fibroblast growth factor, FGF-9, and confirmed its importance in signaling smooth muscle cells to wrap around neovessels via upregulation of the PDGF receptor [22] .
The establishment of a functional microvascular network requires coordinated delivery of several key factors. As mentioned previously, the presentation of a single factor such as VEGF is not sufficient to form functional conduits and can, in contrast, lead to induction of tortuous and leaky vessels [17] . In addition, spatial and temporal regulation of growth factor expression can help ensure accurate vessel growth and remodeling. It is for these reasons that the most successful tissue engineering strategies are based on carefully orchestrated methodologies combining established biochemical factors and biophysical supports.
ASSESSING THE ANGIOGENIC RESPONSE
An important consideration in designing biomaterials for angiogenic purposes is the method by which vessel development, and especially functional vessel development, will be assessed. Three in vivo angiogenesis assays are commonly used throughout the literature to evaluate the response of vessels to externally applied stimuli: the chorioallantoic membrane (CAM), the dorsal skinfold, and cornea micropocket. The CAM is an extra-embryonic membrane of the avian egg that functions as a gas exchange surface during the 21 days prior to chick hatching. CAM assays were originally developed to study embryonic tissue grafts and involve breaking open an egg in order to apply the experimental substance to the exposed membrane surface. Advantages of the CAM assay include low cost, ease of access to chick eggs, and low immunogenicity due to the lack of a mature immune system. However, new angiogenesis in response to treatment must be distinguished from background CAM vessels and angiogenic efficacy using this assay is limited to ten days due to the continual development of the embryo. Further hindering the utility of this assessment method is the fact that genetic modifications to chicks is limited [23] .
In order to study angiogenesis in rodents, which are amenable to genetic modification, the dorsal skinfold chamber can be used. In this technique, the experiment is carried out within a transparent backpack window that is placed over the skinfold, providing ease of visualization for the duration of study [24] . On the other hand, experimental protocols are limited in that implants are restricted in size to approximately 5 mm in diameter and 1 mm in height, and as with the CAM assay, neovessels must be carefully distinguished from the background microvasculature.
A third in vivo angiogenesis assay is conducted in the mouse cornea, which is a site easily accessed and visualized even in live animals and over long time course studies. The greatest benefit of this implant site, however, is that the cornea is naturally transparent and avascular meaning that there are no background vessels to consider during assessment. The cornea micropocket angiogenesis assay, as shown in Fig. (3) , takes advantage of the potential to induce neovascularization in the cornea by stimulating the surrounding limbic vessels to branch and invade the cornea stroma in response to implantation of an angiogenic biomaterial [25] . Additionally, the cornea enables visualization of the developing vasculature over time by allowing imaging of live animals. Although this implant site also necessitates restrictions on implant size, the cornea micropocket assay provides a well established, quantitative, and reproducible technique for gauging the effectiveness of strategies for inducing de novo vessel formation in vivo [25] . Fig. (3) . The mouse cornea micropocket assay. In preparation for the implant, the eye is anesthetized (A) and a partial-thickness incision is made (B). A micropocket is created by separating the stromal layers (C) and the therapeutic device is inserted (D). The ability of the device to promote invasion of the natural limbic vessels into the cornea stroma is assessed (E). Adapted from [29] .
Semi-quantitative and quantitative measurements have been used to characterize induced vessel formation in an effort to better design conduits that mimic host vessels [26] . The mouse cornea micropocket assay provides an ideal location to quantify vessel parameters since it is naturally avascular and, therefore, no background vessels need to be subtracted in the analysis. Induction of new vessels can be quantified via area of neovascularization as utilized in Cao et al. [27] . The number of vessel branch points and vessel diameter have also been quantified in the mouse cornea [28] , as well as blood flow rate, which helps to identify functional vessels [29, 30] . In order to parse out more precise differences in vessel formation, automated space filling parameters have been used in addition to traditional measurements. For example, quantifying space filling properties of the microvasculature have enabled the identification of aberrant vessels, which could not otherwise be detected [31, 32] . These space filling methods, including fractal dimension [33, 34] , lacunarity [35] [36] [37] , and vessel density [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] are scaleinvariant measures of vessel distribution, which is key to ensure scalability in design [48] [49] [50] [51] . The fractal dimension identifies the complexity of the vessel network. Lacunarity examines cell arrangement in terms of non-uniformity by quantifying the gaps (lacunae) of the network [52] . Vessel density describes how much of the space is filled with vessel structures. In total these metrics provide a means to compare therapies and to evaluate the functionality of engineered vessels, both of which can aid the development of successful angiogenic strategies.
BIOMATERIALS FOR GUIDING VESSEL GROWTH
Many biomaterials have been investigated as vehicles for the delivery of angiogenic growth factors or as scaffolds to guide the development of neovessles from transplanted or host cells. These biomaterials would ideally enable neovessel formation with minimal immune response, induce vessels of similar design to native, and biodegrade after vessel induction. Natural materials that are either derived from or analogous to the components of the natural ECM are commonly used, including collagen and its gelatin derivatives, fibrin, and alginate. Collagen is naturally degraded by cell-secreted matrix metalloproteinases (MMPs), specifically collagenases and serine proteases, allowing cellular infiltration and matrix remodeling. Furthermore, the mechanical properties of collagen matrices can be enhanced with the addition of chemical crosslinkers [53] . Fibrin is a natural component of clots formed in the wound healing cascade and provides both structural and biochemical cues to developing tissues [54] . Fibrin can provide a reservoir for growth factors, including those capable of inducing endothelial cell tubulogenesis in vitro. Alginate and chitosan are hydrophilic, linear polysaccharides that have both been used in vivo. Alginate, commonly isolated from brown seaweed and bacteria, is readily available and forms gels under gentle conditions to allow optimal biocompatibility as a tissue scaffold [53] .
Although natural materials have certain inherent biological advantages, synthetic polymers are often used as scaffolds because they allow more precise modification of various material parameters, such as mechanical properties, degradation rates, and drug delivery profiles. Alterations of material properties based on changes in molecular weights, chemical structures, and crosslinking modes make synthetic polymers tunable and provide a wide range of options for regenerative medicine applications. The most highly researched synthetic biomaterial is poly(lactide-co-glycolide) (PLGA) which is a family of polymers based on different ratios of glycolic acid and lactic acid that can be formulated to tailor specific degradation and drug release rates. Additionally, PLGA degrades by hydrolysis into two biocompatible components further solidifying its applicability as an implant material [54] . Polyurethanes are another type of synthetic material used for their biocompatibility and versatility. Although polyurethanes have been previously fabricated into heart valves and dialysis membranes, they have only recently been adapted for angiogenesis applications due to issues surrounding their biodegradation [54] .
Poly(ethylene glycol) diacrylate (PEGDA), is an FDA approved, biocompatible polymer. PEGDA resists protein absorption and subsequent non-specific cell adhesion, thus providing a "blank slate" that can be modified with bioactive ligands to create desired biofunctionality, including specific cell adhesion or cell-directed degradation [55] . PEGDA hydrogels are hydrophilic materials with tunable mechanical properties allowing alteration of stiffness, strength, and viscoelastic characteristics in a manner that generates materials capable of mimicking various tissues in the body [56] [57] [58] . PEGDA can be photopolymerized via light by incorporating a photosensitive chemical into the polymer solution, and mild crosslinking conditions enable cellular encapsulation into the material while maintaining cell viability. Bioactivity is commonly incorporated into PEGDA hydrogels by attaching the free amine or carboxyl group of a peptide or protein to a bifunctional poly(ethylene glycol) (PEG) molecule, leaving the other end to crosslink into the hydrogel. For example, several bioactive oligopeptides known to interact with cell surface receptors have been incorporated into the hydrogel, including the ubiquitous, ECM-derived arg-gly-asp-ser (RGDS) [57, 59] .
GROWTH FACTOR RELEASE FROM BIOMATERI-ALS
One application of biomaterials in the development of neovasculature involves employing polymer scaffolds as delivery vehicles for the growth factors involved in angiogenesis. A fibrin matrix loaded with soluble VEGF, for example, was shown to decrease necrosis and increase neovessel formation in rat dorsal skin ischemic flaps when compared to unloaded controls [60] . Work using the mouse cornea micropocket assay demonstrates that PEGDA hydrogels are effective delivery mediums as shown by the robust vascular response to VEGF-releasing implants in Fig. (4B) [61] . In this mouse model, endothelial cells are genetically modified to express the Flk1-myr::mCherry fluorescent tag, making visualization of vessel elaboration facile and clearly highlighting the potent response of surrounding vasculature to the released growth factor.
In later work, the functionality of these VEGF-induced vessels was demonstrated by evidence of their perfusion with 70 kDa Dextran-Texas red solution that had been injected intravenously into the mice (Fig. (5) ) [62] . Other researchers have shown that bFGF release enhances angiogenesis using delivery systems formulated of heparin/alginate [63] , gelatin [64] , and chitosan [65] , and that PDGF-BB released from PLGA microspheres within a nanofibrous scaffold results in increased blood vessel number in an in vivo soft tissue wound repair model [66] . Fig. (4) . VEGF-releasing PEGDA hydrogels stimulate myr::mCherry+ vessels. Limbic vessels visible in the control hydrogel (A) are stimulated to aggressively invade an implant releasing VEGF (B). Image adapted from [61] . In order to better mimic the natural angiogenic process, combinations of growth factors have been released from biomaterials as well [67] [68] [69] . For example, an in vivo matrigel plug assay was used to illicit the effects of a combination of FGF-2 and VEGF, finding that VEGF enhances endothelial cell PDGF-B release, while FGF-2 up-regulates mural PDGF receptor (PDGFR-) expression. The combinations of the factors also stimulated significant mural cell recruitment, which is necessary for a functional vessel [70] . Notably, the combination of VEGF and PDGF is not used based on evidence that VEGF-mediated activation of VEGFR-2 suppresses PDGFR-expression in mural cells [71] thereby actually limiting the vascular response.
Seminal work by Cao et al. in the mouse cornea and ischemic hindlimb models investigated three combinations of growth factors including VEGF and FGF-2, VEGF and PDGF-BB, and FGF-2 and PDGF-BB [27] . Growth factors were combined in sucrose aluminum sulfate pellets coated with a hydron polymer for long-term release in vivo. As clearly demonstrated in the cornea work, there is a significant increase in the vascular response when FGF-2 and PDGF-BB were delivered concurrently as compared to the other growth factor formulations (Fig. (6) ). When this synergy was further investigated on a molecular level, results suggested that vascular endothelial cells are unresponsive to PDGF until activated by FGF. Within the endothelial cells, FGF transcriptionally triggers PDGF receptor expression and binding of the PDGF-BB ligand, which then induces a positive feedback signal in the form of an amplification of FGF-2 expression in vascular mural cells [72] . Work along these lines is critical to the formulation of biomaterials for the development of functional microvasculature in vivo and serves as a foundation for more complex material strategies that incorporate cellular components and/or physical cues to precisely engineer the vascular network.
CONTROLLED RELEASE OF GROWTH FACTORS USING BIOMATERIALS
Since growth factors have such substantial effects in the body, many have been examined in clinical trials. However, since even in slow-release applications, high levels of these potent factors circulate in the body, there is the potential to induce significant complications at off-site locations. Release of growth factors can lead to unintended angiogenesis, as seen in pathologies including retinopathy, rheumatoid arthritis, and tumor growth [54] . Circulating VEGF, known to induce vascular permeability, has been associated with transient edema in 34% of patients [73] and multi-organ edema leading to death in a high percentage of animals [74] . Similarly, the combination of VEGF and FGF was shown to induce vasodilation and hypotension through the nitric-oxidemediated pathway, resulting in death of 50% of pigs tested [74] . In clinical trials, delivery of growth factors showed initial promise, but subsequent phase II trials failed to show efficacy [75] .
To improve the cellular response to releasable factors, biomaterials can be designed to control both spatial and temporal characteristics of angiogenic factor presentation. In addition to the undesirable effects mentioned above, many growth factors, including bFGF and VEGF, have a half life in the body of less than one hour [76] , which can limit their overall efficacy or necessitate repeat and/or higher dose applications. Furthermore, control over temporal release can better mimic the natural process of angiogenesis, leading to more stable and functional vessel formation. Ennet et al. examined VEGF release kinetics by combining poly(lactideco-glycolide) scaffolds and microspheres implanted in mice. In order to obtain sustained, local VEGF release for 21 days, polymer composition, matrix composition, and scaffold size were altered [77] . This polymer delivery system was enhanced to accommodate duel-factor release in a carefully tuned timeframe by dissolving VEGF in the bulk polymer while pre-encapsulating PDGF in microspheres [78] . In similar work, both the spatial and temporal release kinetics of VEGF and PDGF-BB were controlled using a porous PLGA scaffold to first deliver VEGF in one spatial region with subsequent release of PDGF-BB in an adjacent area, resulting in more mature vessels in vivo [79] .
Because blood vessels and many other tissues operate in mechanically dynamic environments, physical cues have also been used to trigger growth factor release from biomaterials. As example, VEGF was reversibly bound to an alginate hydrogel carrier with delivery in response to a compressive load stimulating a VEGF-induced vessel response [76] . Although these and other strategies have provided various means for tailoring the release of angiogenic factors into ischemic tissues, there is still a need for materials that can provide sustained signaling and specifically-directed vessel development by incorporating biochemical molecules and even cellular components into the scaffold framework.
BIOMATERIALS WITH IMMOBILIZED GROWTH FACTORS
Growth factors covalently attached to matrices can enable prolonged delivery and locally concentrated bioactivity. Such materials can be considered as mimetic of the natural immobilization of signaling molecules by heparan sulfate proteoglycans, fibrin, and other components of the ECM. Covalent immobilization stabilizes these growth factors by protecting them from degradation and creating long-term reservoirs that can be exploited as needed for growth or repair of tissue. Several investigators have used naturally occurring binding factors to restrict angiogenic proteins to matrices with results indicating successful induction of neovascularization in vivo [80] [81] [82] . Perhaps more popular, however, is the use of synthetic analogs to these adhesive molecules. Maynard et al. created a sulfated tetrapeptide which mimics heparin binding to VEGF as an improvement over natural heparin, which is often heterogeneous and difficult to modify [83] . Koch et al. similarly used a synthetic homobifunctional polymer cross-linker, disuccinimidyl disuccinate poly(ethylene glycol), to attach VEGF to collagen matrices [84] .
As mentioned previously, synthetic PEGDA hydrogels are also amenable to covalent functionalization. Heterobifunctional PEG linkers have been used to attach a wide variety of peptides and proteins to these hydrated matrices. Several factors, including VEGF, PDGF, FGF, and cell surface ligands of the ephrin family, have been specifically studied for their angiogenic effects. PEG-ephrinA1 immoblized to hydrogel surfaces induced endothelial cell tubulogenesis with luminal diameters in the range of 5-30 μm, creating structures resembling early stage capillaries as shown in Fig. (7) [85] . In a separate study, PEG-VEGF not only increased endothelial cell tubulogenesis, but also increased endothelial cell motility 14-fold and cell-cell connections 3- Fig. (6) . Angiogenic effects of growth factors in the mouse cornea. Corneal neovascularization in response to growth factor delivery was examined over the course of 120 days. Arrows indicate the implanted growth factor-releasing pellets; asterisks indicate positions of pellets in those corneas that lost implanted pellets. The synergistic effect of FGF-2 and PDGF-BB is clearly demonstrated in this work. Adapted from [27] .
fold in a three-dimensional, biodegradable hydrogel [86] . In each case, the PEGDA hydrogel was shown to be permissive of cell viability, migration, and organization in cultures of up to 30 days. Exciting results were recently published using a combination approach to growth factor presentation wherein a soluble PDGF molecule stimulated host vessel growth into the mouse cornea, which was then stabilized and significantly enhanced in the presence of covalently immobilized PEG-ephrinA1 [87] . These results confirm the ability of synthetic biomaterials to serve as appropriate scaffolds for engineered vessel formation and suggest further study of more complex, multi-modal design strategies to help progress these technologies further toward functional vessels capable of anastomosing with host vasculature in vivo. 
CELLULAR ENCAPSULATION FOR ANGIOGENE-SIS IN BIOMATERIALS
Another approach to microvasculature engineering is to incorporate cells into the biomaterial scaffold. The addition of cells that form tubules, either spontaneously or under biochemical stimulation eliminates the time-delay inherent in recruiting host vessels into the implant material. Additionally, because cells themselves are factories for the soluble molecules necessary to induce capillary formation, the effort to optimize dose and release of growth factors can be significantly diminished. For example, Chen et al. allowed a coculture of human umbilical vein endothelial cells (HUVECs) and fibroblasts to form tubes in vitro for seven days before in vivo implantation. Scaffolds containing pre-formed tubes led to anastomosis with the host vasculature within 5 days as compared to 14 days for scaffolds without pre-formed tubes. Furthermore, the number and area of perfused lumens was significantly higher in the prevascularized scaffolds [88] .
A wide variety of cell sources have been investigated for the purpose of vascularizing engineered materials including: endothelial cells, pericyte precursors, mesenchymal stem cells, endothelial progenitor cells, and embryonic stem cells. Nor et al. showed the feasibility of the cell encapsulation approach when human dermal microvascular endothelial cells (HDMEC) seeded on poly L-lactic acid (PLLA) scaffolds formed functional vessels, which then anastomosed with the mouse vasculature following implantation [89] . The vascular response was further enhanced when HDMECs were co-cultured with human osteoblasts within a biomaterial composed of hydroxyapatite, calcium phosphate, and nickel titanium [90] . Carrying on with the same co-culture, the authors later employed a silk fibroin scaffold and demonstrated that tubules preformed in vitro could form functional anastomoses with host vasculature once implanted. In addition, the presence of the cells aided in the recruitment of host vessels into the scaffold material, an important step towards generating a successful bone graft [91] . In other work, a coculture of three cell types -keratinocytes, fibroblasts, and endothelial cells -decreased the time to form capillary-like structures in a skin substitute from fourteen days to four days [92] . Koike et al. formed long-term stable vessels when HUVECs were used alone and in combination with pericyte precursor cells (10T1/2) on a fibronectin-type I collagen matrix as seen in Fig. (8) below [8] . Similarly, work by Jain and colleagues showed that HUVECs encapsulated in a scaffold and implanted in vivo formed vessels with minimal perfusion, but with the addition of 10T1/2 cells, the culture formed a functional vascular network that persisted in connection with the host circulatory system up to one year later [93] . As further evidence of the maturity of the engineered microvascular network, 10T1/2 pericyte precursor cells co-cultured with HUVECs displayed a smooth muscle cell morphology and began expressing pericyte markers, such as -smooth muscle actin, smooth muscle myosin, and calponin [94] . Endothelial progenitor cells (EPCs), identified in 1997 in human peripheral blood as a key player in adult neovascularization, have also been used in therapeutic angiogenesis. These cells begin as mononuclear hematopoietic progenitor cells and are released from the bone marrow into peripheral circulation upon a physiological stimulus to differentiate into endothelial cells as part of the vasculogenesis process. Endothelial progenitor cells seeded on top of a monolayer of bovine microvascular endothelial cells on collagen gels promoted increased length, number, and depth of blood vessel network formation [95] . Stem cells, too, have been highly studied for their ability to differentiate into endothelial cells, pericytes, and even beating cardiomyocytes [96] . Human embryonic stem cells, differentiated into endothelial-like cells and used in a biodegradable scaffold of poly-(L-lactic acid) and PLGA, showed an angiogenic response in SCID mice and an ischemic hindlimb [97, 98] . When the differentiated endothelial-like cells were combined with 10T1/2 cells, the tubule structures were observed after only two days in vivo [99] . In more recent work, Chen et al. demonstrated significant differences in the rate of functional anastomosis formation when comparing EPC-derived endothelial cells to HUVECs [100] . EPCs were isolated from cord blood and expanded in culture prior to combining with fibroblasts in a fibrinogen matrix. After allowing tubules to form in vitro, the matrices were implanted in mice and showed signs of anastomosis within the first 24 hours. A remarkable 90% of construct tubules were perfused by day 3, compared to only 33% of those in constructs where HUVECs were used as the endothelial cell component, highlighting the potency of these progenitor cells. Other stem cells sources, including hematopoietic stem cells and mesenchymal stem cells in the bone marrow have also shown promise in inducing a vascular response [101] .
Despite many recent successes, challenges to in vitro prevascularization remain. Oftentimes long culture periods are required to allow encapsulated cells to spontaneously form patent networks suitable for implantation. The timing can be critical since many cells are difficult to maintain in long-term culture environments. To address this issue, response of encapsulated cells has been further enhanced with the addition of growth factors. Relatively low doses of growth factors can be used to act upon transplanted vessel-forming cells to promote survival, proliferation, and differentiation. Peters et al. showed functional vessels were formed after seven days when human microvascular endothelial cells were seeded in PLGA with VEGF [102] . A combination of dermal fibroblasts and HUVECs showed significantly more capillary formation in response to bFGF and VEGF [103] in the matrix. Frerich et al. enhanced capillary formation in a fibrin-microcarrier scaffold by combining two cell types, HUVECs and stromal cells from adipose tissue, along with two growth factors, VEGF to stimulate angiogenesis and insulin-like growth factor (IGF)-1 to stabilize the capillary structures [104] .
Rather than deliver growth factors in a combined approach, several investigators have transfected cells to overexpress angiogenic growth factor genes as a way to ensure prolonged, local growth factor delivery [105] [106] [107] . As example mononuclear cells, which give rise to endothelial progenitor cells, were transfected to overexpress VEGF. thereby stimulating their differentiation into endothelial cells for vasculogenesis while at the same time enhancing local angiogenesis [105] . Myoblasts have also been transfected to express VEGF [106] and bFGF [107] to improve vascularity in engineered muscle tissue. Cellular encapsulation in combination with growth factor release remains a promising area of research.
INNOVATIVE BIOMATERIAL DESIGN
Alternative methods to induce and establish functional vascular networks in engineered tissues include novel techniques for rapidly promoting vessel growth prior to transplanting the material to the target site. These methodologies build on the previously discussed work to focus primarily on decreasing the time to anastomosis and generate neovessel networks that posses precisely controlled geometries. For example, a fibrin gel containing a polyurethane mesh and releasing VEGF was grown in CAM tissue to enable in vivo prevascularization in this proangiogenic environment. Once the polyurethane mesh was penetrated by capillary networks, it underwent a freeze-thaw cycle prior to subcutaneous implantation in rats. Revascularization of the networks occurred within three days of implantation, possibly due to enhanced adhesion from ECM proteins such as collagen IV and laminin from preformed capillaries or due to a chemotactic effect from cell remnants in the mesh [108] .
In an effort to physically guide pre-vascular cells, Stosich et al. created cylindrical channels within hydrogel scaffolds and examined the effects of these patterned networks on vessel formation when combined with bFGF release. Hydrogels with channels but without bFGF showed host infiltration only in the microchannels, and hydrogels with bFGF but without microchannels showed random and isolated areas of vessel infiltration. Hydrogels containing both bFGF and microchannels showed significant infiltration into the channels indicating the ability to spatially direct vessel establishment [109] . Towards a similar goal, Okano and colleagues employed a thermo-responsive substrate micropatterened with 20 m-wide cell-adhesive lanes to direct endothelial cell growth along the striped surface features. The researchers then harvested and layered the endothelial cells sheets with alternating fibroblast monolayers to generate 3D cell constructs [110] . After an additional 5-day culture period, microvascular-like networks developed in the pattern of the original adhesive lanes. This novel technique presents another method to tune vessel development within biomaterials for individual regenerative medicine applications.
CONCLUSION
The field of tissue engineering is greatly expanding with efforts to create functional engineered counterparts for damaged tissues. Much recent research has focused on the development of a functional microvasculature network within these new materials since tissue nourishment is critical to survival, especially as engineered constructs become larger and more biologically complex. As discussed in this review, many strategies use growth factors to initiate an angiogenic response in processes that mimic those of vessel formation in vivo. Variations in both natural and synthetic biomaterials provide a wealth of options for finely tuning the presentation of signaling molecules in order to achieve the most appropriate vascular response for a particular tissue type. Future studies to ascertain the precise temporal and spatial appearance of cellular components and signaling factors will help guide the establishment of stable, functional vessels that efficiently anastomose to the host in a timeframe suitable for clinical application.
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